FOR THE TREATMENT OF ADULT
PATIENTS WITH MODERATELY TO
SEVERELY ACTIVE CROHN’S DISEASE

Superiority of
TREMFYA vs STELARA^®
(ustekinumab) was
assessed in
pivotal trials*This is based on information licensed from
NPA/DDD with business rules applied and
captures only approved induction doses of
IL-23 inhibitors for adults
with moderately to
severely active Crohn’s disease or ulcerative
colitis. Data used to support this are from
2/21/2026 - 3/27/2026.

*Based on a pooled analysis of GALAXI 2 and GALAXI 3.²

^†Deep remission was defined as achieving both clinical remission (CDAI score <150) and endoscopic remission (SES-CD ≤4 and at least a 2-point reduction from baseline and no subscore greater than 1 in any individual component).²

^‡Endoscopic response was defined as ≥50% improvement from baseline in SES-CD score or SES-CD Score ≤2.²

^§Clinical remission defined as CDAI score <150.²

^||Endoscopic remission defined as SES-CD ≤4 and a ≥2-point reduction from baseline and no subscore greater than 1 in any individual component.²

CDAI=Crohn’s Disease Activity Index; DDD=Drug Distribution Data; IL-23=interleukin-23; IL-23i=interleukin-23 inhibitor; IV=intravenous; NPA=National Prescription Audit; q4w=every 4 weeks; q8w=every 8 weeks; SC=subcutaneous; SES-CD=Simple Endoscopic Score for Crohn’s Disease; UC=ulcerative colitis.